Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Patient of Monroe Carell Jr. Children's Hospital at Vanderbilt First in World to Receive New Investigational Gene Editing Therapy


 

A 9-year-old patient of Monroe Carell Jr. Children's Hospital at Vanderbilt is the first in the world to receive an investigational gene editing therapy for Methylmalonic Acidemia (MMA), a rare genetic disorder diagnosed at birth.

On May 29, Eddie Axelson, of Clarksville, Tennessee, received LogicBio Therapeutics' investigational single-administration targeted gene-editing therapy, hLB-001, which seeks to correct MMA, an inborn metabolism disorder in which the body cannot properly process protein from food.

Axelson received the dose of hLB-001, administered via IV infusion, as part of LogicBio's SUNRISE multicenter clinical trial. The study will assess the safety, tolerability and effectiveness of this potential gene editing therapy for MMA.

The investigational gene therapy, created by LogicBio Therapeutics, also marks the first-ever such genetic therapy administered for a biochemical disorder at Children's Hospital and Vanderbilt University Medical Center.

"This is a gene editing trial in which we use a harmless virus to transport the missing gene into liver cells, so that the liver cells will start producing the deficient enzyme to correct the defect in body chemistry," said Thomas Morgan, MD, associate professor of Pediatrics and Genetics and lead principal investigator for the study at Vanderbilt.

People with MMA have too much methylmalonic acid in their blood because their livers can't break down certain fats and protein building blocks, specifically four amino acids known by the acronym VOMIT (valine, odd chain fatty acids, methionine, isoleucine and threonine). Currently, the only treatment is to restrict protein in a patient's diet and to provide a special formula without the four amino acids.

"While the current treatment is usually adequate, it's not good enough to keep kids from getting sick or potentially needing a liver transplant or a combined kidney and liver transplant later in life," Morgan said. "If this works, it could alter the DNA in the liver so that it fixes the problem for the rest of the patient's life, potentially sparing them the need for a transplant in the future."

The hLB-001 gene editing therapy is designed to use an engineered adeno-associated virus to precisely deliver a working copy of the mutase gene to the patient's hepatocytes and integrate it right next to another gene called albumin, the most highly active gene in the liver. In this way, albumin drives the production of the mutase enzyme, with the goal of replacing enough mutase activity to improve the patient's metabolic status.

MMA is diagnosed at birth through the state's newborn screening ­- a simple heel stick blood sample at birth used to check for numerous diseases. Tennessee currently screens for 71 conditions, including MMA. In the first few days of life, a newborn's symptoms can include vomiting, dehydration, weak muscle tone, lethargy and failure to thrive. MMA occurs in about 1 in 50,000 live births, affecting males and females from all demographics.

Children can see long periods of stability where the acid levels can be controlled. But if they get a viral infection, they can become extremely sick and often need intensive care in the hospital. Long-term consequences of the disorder can include damage to all organs, including the brain, the liver and the kidneys.

Children's Hospital is one of seven sites participating in the SUNRISE trial, which seeks to enroll eight patients over the study period. Eligible participants are children with MMA, whose MMA is caused by mutation in the methylmalonyl-CoA mutase gene, or MMUT, and who are 6 months to 12 years of age. Initially, the trial will start with patients ages 3 to 12 years old.

Patients must be in stable health for two months prior to enrolling. Following infusion, participants in the trial will have regular screening follow-ups.

 
Share:

Related Articles:


Recent Articles

AACR Establishes New Cancer Evolution Working Group

The American Association for Cancer Research (AACR) announced the formation of its seventh and newest scientific working group, which will be dedicated to supporting cancer evolution research.

Read More

Global Dementia Cases Forecasted To Triple By 2050

New analysis shows a decrease in prevalence due to education countered by increase due to heart health risk factors

Read More

Blackburn, Feinstein Introduce Bill to Protect Access to Breast Cancer Screenings

U.S. Senators Marsha Blackburn (R-Tenn.) and Dianne Feinstein (D-Calif.) today introduced the Protecting Access to Lifesaving Screenings (PALS) Act of 2021, a bill to preserve coverage for routine breast cancer screening for women beginning at age 40.

Read More

CUMBERLAND PHARMACEUTICALS REPORTS 2.5M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2020

The company's 2020 sustainability report highlights its commitment to environmental, social and governance (ESG) activities

Read More

Mobile Mentor Named Winner of Microsoft's 2021 Partner of the Year for Modern Endpoint Management

Mobile Mentor announced they have been awarded the 2021 Global Partner of the Year Award for Modern Endpoint Management.

Read More

Alzheimer's Association Welcomes CMS Announcement of National Coverage Determination Analysis on Treatment for Alzheimer's Disease

On behalf of all those living with Alzheimer's disease, their caregivers, and their families, we appreciate the Centers for Medicare & Medicaid Services (CMS) thoughtful consideration on coverage considerations for monoclonal antibodies targeting amyloid for the treatment of Alzheimer's disease, including aducanumab, which was recently approved by the Food and Drug Administration (FDA).

Read More

HCTec Acquires Talon Healthy IT Services

Healthcare IT firm adds industry-leading help desk service company to portfolio of solutions

Read More

The Seven Steps of Revenue Cycle for a Healthcare Practice

Revenue cycle management tracks patient revenue from the initial encounter with the healthcare system to payment of balance. Getting the seven steps of revenue cycle right helps providers avoid missteps that are costly to the bottom line.

Read More

Expanding Evidence-Based Care for Dementia

The Alzheimer's Association is on a mission to ensure care professionals have access to evidence-based training to ensure those with dementia receive quality care across all settings.

Read More

A Natural Leader

Nashville physician Dr. Ryan Mire to head nation's largest medical-specialty society.

Read More

Email Print
 
 

 

 


Tags:
9, and mom, Patient Eddie Axelson, play Legos as Kim Bettis, prepares to give Eddie the first-ever dose of LogicBio Therapeutics' single-admi, RN, Tanya Axelson
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: